RxDoctor Payments Data

Prachi Thapar

Dallas, TXNPI 1851973945

Payments from drug & device makers

$2,267in general payments, 2019–2025

Across 83 payments — averaging $27.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$511
  • Boehringer Ingelheim$279
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$227
  • Pfizer$217
  • Novo Nordisk$200
  • AbbVie$141
  • plus $692 from 15 others

What the payments were for

  • Food & beverage$2,267100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Atorvastatin Calcium18$65
Metformin Hcl11$22
Amlodipine Besylate14$12

Paid to pharmacies, not to this prescriber.

Where these figures come from

Is this you, or does something look wrong? →